- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-CATD/ CTSD/ CLN10 functional antibody
Anti-CATD/ CTSD/ CLN10 functional antibody for cell culture, ELISA & in-vivo assay
Go to CTSD/CTSD products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T67102-Ab-1/ GM-Tg-hg-T67102-Ab-2 | Anti-Human CTSD monoclonal antibody | Human |
| GM-Tg-rg-T67102-Ab-1/ GM-Tg-rg-T67102-Ab-2 | Anti-Rat CTSD monoclonal antibody | Rat |
| GM-Tg-mg-T67102-Ab-1/ GM-Tg-mg-T67102-Ab-2 | Anti-Mouse CTSD monoclonal antibody | Mouse |
| GM-Tg-cynog-T67102-Ab-1/ GM-Tg-cynog-T67102-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CTSD monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T67102-Ab-1/ GM-Tg-felg-T67102-Ab-2 | Anti-Feline CTSD monoclonal antibody | Feline |
| GM-Tg-cang-T67102-Ab-1/ GM-Tg-cang-T67102-Ab-2 | Anti-Canine CTSD monoclonal antibody | Canine |
| GM-Tg-bovg-T67102-Ab-1/ GM-Tg-bovg-T67102-Ab-2 | Anti-Bovine CTSD monoclonal antibody | Bovine |
| GM-Tg-equg-T67102-Ab-1/ GM-Tg-equg-T67102-Ab-2 | Anti-Equine CTSD monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T67102-Ab-1/ GM-Tg-hg-T67102-Ab-2; GM-Tg-rg-T67102-Ab-1/ GM-Tg-rg-T67102-Ab-2; GM-Tg-mg-T67102-Ab-1/ GM-Tg-mg-T67102-Ab-2; GM-Tg-cynog-T67102-Ab-1/ GM-Tg-cynog-T67102-Ab-2; GM-Tg-felg-T67102-Ab-1/ GM-Tg-felg-T67102-Ab-2; GM-Tg-cang-T67102-Ab-1/ GM-Tg-cang-T67102-Ab-2; GM-Tg-bovg-T67102-Ab-1/ GM-Tg-bovg-T67102-Ab-2; GM-Tg-equg-T67102-Ab-1/ GM-Tg-equg-T67102-Ab-2 |
| Products Name | Anti-CTSD monoclonal antibody |
| Format | mab |
| Target Name | CTSD |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-CTSD benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-T67102-Ag-1 | Recombinant multi-species CATD/ CTSD/ CLN10 protein |
| ORF Viral Vector | pGMAP000223 | Human CTSD Adenovirus plasmid |
| ORF Viral Vector | pGMLP000108 | human CTSD Lentivirus plasmid |
| ORF Viral Vector | vGMAP000192 | Human CTSD Adenovirus particle |
| ORF Viral Vector | vGMLP000108 | human CTSD Lentivirus particle |
| ORF Viral Vector | vGMAP000223 | Human CTSD Adenovirus particle |
| ORF Viral Vector | pGMAP000192 | Human CTSD Adenovirus plasmid |
| ORF Viral Vector | pGMLPm002184 | mouse Ctsd Lentivirus plasmid |
| ORF Viral Vector | vGMLPm002184 | mouse Ctsd Lentivirus particle |
Target information
| Target ID | GM-T67102 |
| Target Name | CTSD |
| Gene ID | 1509,13033,171293,703534,483662,101094625,282883,100629639 |
| Gene Symbol and Synonyms | CatD,CD,CLN10,CPSD,CTSD,HEL-S-130P |
| Uniprot Accession | P07339,P24268,Q4LAL9,P80209 |
| Uniprot Entry Name | CATD_HUMAN,CATD_RAT,CATD_CANLF,CATD_BOVIN |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category | Therapeutics Target |
| Disease | colorectal cancer, Malignant neoplasm of bladder |
| Gene Ensembl | ENSG00000117984 |
| Target Classification | N/A |
The target: CTSD, gene name: CTSD, also named as CLN10, CPSD, HEL-S-130P. This gene encodes a member of the A1 family of peptidases. The encoded preproprotein is proteolytically processed to generate multiple protein products. These products include the cathepsin D light and heavy chains, which heterodimerize to form the mature enzyme. This enzyme exhibits pepsin-like activity and plays a role in protein turnover and in the proteolytic activation of hormones and growth factors. Mutations in this gene play a causal role in neuronal ceroid lipofuscinosis-10 and may be involved in the pathogenesis of several other diseases, including breast cancer and possibly Alzheimer's disease. [provided by RefSeq, Nov 2015].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
